Bill Panagiotakopolous, COO of Beleave Inc. (BE:CN) discusses this medical marijuana company’s future plans.
Beleave is a company in the late stages of licensing for Health Canada’s Medical Marijuana Program. We operate an indoor facility in Hamilton, Ontario that has been built to exceed regulatory requirements. The property has lots of room to expand, should demand necessitate.
Concurrent to pursuing a license, we have been actively strengthening our team of professionals with the goal of being one of the best rounded in the industry. Strategically chosen members ensure that once licensed we will have a competitive advantage in the area such as cultivation, distribution, construction, patient acquisition and patent development.
Through leveraging relationship, we have maintained one of the industry’s lowest construction and compliance cost resulting a minimal shareholder dilution. We are working under a Federal Cannabis Research License with our partners at Ryerson University on cannabis plant genetics optimizing extraction techniques to develop proprietary products. We have a proven track record of success. Once licensed, this will be integrated into branded and patented products that will become the industry standard and the intellectual property that comes of this should add tremendous value to our shareholders. As a research forward company, it is important for us to take a leadership role in the space to ensure a consistent and high quality product reaches the consumer.